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Abstract
Crohn’s disease and ulcerative colitis are the two most prevalent inflammatory bowel diseases (IBDs) in Jewish and Caucasian popu-
lations, affecting as many as one in 250 individuals. Nevertheless, the underlying causes of both disorders are not yet fully understood 
and remain unknown. However, current evidence suggests that the exaggerated inflammatory response, more commonly referred 
to as IBD, is believed to arise from dysregulation of the gastrointestinal (GI) immune system in genetically predisposed individuals 
who are exposed to environmental triggers. Recent advances have identified multiple IBD susceptibility genes; however, only a few 
environmental determinants of IBD have been consistently identified. The difficulty in understanding the etiology of IBD is in part 
due to the complex interactions between genes and the environment. Additionally, autoimmune mechanisms are believed to play 
a role in the development of IBDs, but the target antigens and the underlying pathways have not been sufficiently characterized 
and identified. IBD is commonly referred to as an “idiopathic disease;” a disease with an unknown cause (Health &Medicine, 2016; 
Sartor, 2006). This paper examines the possible causes of IBD, specifically highlighting Crohn’s disease.
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Crohn’s Disease (CD) is a chronic autoimmune disease 
mainly affecting the gastrointestinal (GI) tract extending 
from the mouth to the anus; however, it’s most com-
monly found in the ilium, leading to the alternate name 
ileitis (Newman & Siminovitch, 2003). It’s characterized 
by thickened areas of the GI wall with inflammation 
extending through all four layers including the mucosa, 
submucosa, muscularis externa, and serosa (Politics & 
Government week, 2017; Ruthruff, 2007). The inflam-
mation is somewhat similar to that of ulcerative colitis, 
and commonly leads to abdominal pain, diarrhea, vom-
iting, weight loss, anemia and fever (Torres et al. 2017). 
However, some patients may experience mouth and skin 
sores along with joint stiffness and swelling (Creek, 2017). 
Unfortunately, patients suffering from CD are at a higher 
risk of developing other autoimmune disorders such as 
osteoporosis, thyroid disease, as well as colorectal can-
cer (Baumgart & Sandborn, 2012; O’Sullivan, 2009; Bae 
et al. 2014). Symptoms range from mild to severe and 
treatment varies depending on the severity of the disease. 
Typically, a doctor will perform a series of tests before 
confirming CD. These tests may include a physical exam, 
lab tests, stool samples, CT scans, MRI, endoscopy and 
a colonoscopy (Baumgart & Sandborn, 2012), in which 
a small flexible camera is inserted through the rectum 
to distinguish abnormalities. Together, these tests detect 
abnormalities which may exist throughout the intestinal 
track thus indicating IBD.
While there is currently no known cure for CD, treat-
ment options are available (Akobeng, 2008; Michail et al. 
2013). It is estimated that roughly ten percent of patients 
who undergo surgery will have prolonged clinical remis-
sion (Baumgart, 2012; D’Incà & Caccaro, 2014). The goal 
of treatment is to reduce inflammation and to improve 
the prognosis by limiting complications (Newman & 
Siminovitch, 2003). Noninvasive treatment options in-
clude anti-inflammatory medication, antibiotics, and im-
munosuppressant drugs. Anti-inflammatory medication 
controls and suppresses inflammation, thereby decreasing 
the frequency of flare ups. With proper treatment over 
time, periods of remission can be extended, and flare ups 
can be reduced. Alternatively, immunosuppressant med-
ications, such as corticosteroids, aid by suppressing the 
immune system, thus allowing the intestinal tissue to heal. 
However, in some instances, more invasive treatment 
plans are required. Despite significant progress in treat-
ments for CD, it’s estimated that as many as seventy-five 
to ninety percent of patients suffering from the disease 
will undergo surgery to relieve symptoms at some point 
during the patient’s life.  (Politics & Government Week, 
2017; Liu et al. 2017). At times, CD creates complications 
that are deemed a medical emergency, such as a bowel 
abscess, a fistula (which may result from an unaddressed 
abscess), uncontrolled bleeding, or intestinal blockage, in 
which case surgery may be required. As an aside, patients 
may also require surgery as a result of previous medica-
tions having caused severe side effects, or simply because 
the medications have stopped working as effectively as 
the body adapts and immunizes itself against the medica-
tion (Torres et al. 2017).
 There are several types of surgeries that can be per-
formed, the most common one being a bowel resection. 
This involves the removal of all parts of the damaged in-
testine and is performed when parts of the small bowel 
are diseased or blocked (Simon et al. 2003). A partial 
colectomy is another type of bowel resection in which 
the surgeon removes the damaged parts of the colon. It 
can be performed openly or laparoscopically. When per-
formed openly, the surgeon manually cuts an extensive 
incision; alternatively, the surgeon may prefer to work 
laparoscopically, making several small incisions, thereby 
allowing him to work outside the body. In some instanc-
es, a total colectomy is required in which the surgeon 
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removes the entire colon. This is generally required only 
in severe cases in which the colon is highly inflamed, and 
medication is ineffective (Travis, et al. 2011). A colectomy 
often requires further procedures to reattach the discon-
nected portions of the digestive system, thus permitting 
waste to leave the body. For example, in some instances, 
an ostomy is performed. This surgery is categorized as 
a lifesaving procedure as it is performed when stool is 
unable to be eliminated from the body through the rec-
tum (Travis et al. 2011). In this procedure, the colon is 
removed, and a stoma is created on the abdomen. Wastes 
are then allowed to pass through the surgically created 
stoma into an ostomy bag, a prosthetic bag which holds 
stool and can be emptied regularly.
Common risk factors of these surgeries include bleed-
ing, bowel obstruction, infection and pulmonary embolism. 
Methods
Data was collected using ProQuest and PubMed data-
bases through Touro College’s online library. Among the 
key-phrases used were “Crohn’s Disease”, “irritable bowel 
disorder”, “epigenetics”, as well as “hygiene hypothesis.”
Genetic Factors
There is a significant amount of evidence suggesting that 
genetic factors play a key role in the triggers of IBD. Genetic 
mutations lead to the body’s defective defense against mi-
crobes in the digestive system, allowing the immune system 
to attack the lining of the digestive tract, thereby causing 
inflammation indicating IBD. The genetic analysis of complex 
diseases, such as IBD, is difficult to identify for several rea-
sons. First, the disease isn’t categorized into a single entity, 
but rather into groups of heterogeneous disorders, where 
environmental and genetic factors play a significant role in 
disease expression. Additionally, ethnic differences that may 
exist between patients suffering with IBD are associated 
with different mutations (Bae et al. 2014). Other difficulties 
faced include the relatively low frequency of IBD, about .1-.4 
percent,  amongst populations (Michail et al. 2013); statistics 
showing that only about ten  percent, first-degree relatives 
are affected with the same disorder (Sartor, 2006; Pena, 
1998); as well as the presence of genes with minor genetic 
effects, are some of the difficulties faced with when identify-
ing disease susceptibility. Nevertheless, there is an emerging 
understanding of the inherited aspects that predispose an 
individual to IBD (Newman & Siminovitch, 2003).
The evidence for genetic involvement in IBD comes from 
ethnic e.g., Ashkenazic Jews and family-based studies on 
blood relatives affected with CD, associations of IBD with 
known genetic syndromes, diseases with known genetic 
predisposition such as autoimmune diseases, and more 
recently through genetic marker studies (Barber GE, Yajnik 
V, Khalili H, et al. 2016). Various genetic markers have shown 
different levels of correlation with IBD. Some have failed 
to show a consistent association with IBD, including blood 
groups, secretor status, a 1-antitrypsin, and immunoglobulin 
marker genes. Studies on these markers can be divided into 
those in which a genetic element is proven and those in 
which a genetic predisposition may be present (Pena,1998). 
Several polymorphisms in the genes encoding different cy-
tokines and their receptors have been described and are 
potential candidates to be studied scientifically.
There are currently multiple studies being carried out 
to help identify the genetic mutations, causes, and suscepti-
bility in developing IBD. In addition, technological progress 
in genetic testing and DNA sequencing permitted many 
genome-wide association studies (GWAS), which helped 
identify new single nucleotide polymorphisms (Loddo 
& Romano, 2015). Correspondingly, over the past few 
decades, there have been significant advances in the un-
derstanding of genetic causes linked to IBD. (Newman & 
Siminovitch, 2003). The studies described below are popu-
lation-based studies in areas that extend over a period of 
time, making them most likely to give fair, unbiased results. 
These studies have confirmed the increased prevalence 
of IBD in family members as compared to those in the 
general population. These include studies based on twins, 
families, and the Jewish Ashkenazic ethnic group.
The data derived from studies performed on twins pow-
erfully supports the view that IBD is linked to a genetic 
component. There is a significant increase in the concor-
dance of IBD in monozygotic twins compared to dizygotic 
twins, particularly with Crohn’s disease. Twin studies for 
CD have shown fifty percent concordance in monozygot-
ic twins compared to less than ten percent in dizygotic 
twins (Loddo & Romano, 2015). Environment plays only a 
negligible role in predisposition for CD. Indirect evidence 
supporting the necessity of predisposing genes for the de-
velopment of the disease in the presence of a common 
environment is the low prevalence in spouses of patients 
with IBD. Spouses who both suffer from CD, is deemed as 
a highly unusual occurrence, as frequent as can be expect-
ed by chance alone (Dudley, 1995)
 Family-based studies consist of studying linkage analysis 
in sibling pairs and parental transmission in genome-wide 
screening using microsatellite markers. Microsatellite 
markers, otherwise known as simple sequence repeats 
(SSRs), which can be defined as segments of DNA where 
the nucleotide sequence repeats. Familial aggregation of 
IBD has been well documented in North American and 
European studies. It is well established that first degree 
relatives, particularly siblings, are at much greater risk in 
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developing IBD as compared to those in the general pop-
ulation. For example, if one parent has CD, the child has 
a ten percent increased risk in developing CD; and even 
if both parents suffer from CD, that likelihood increases 
to thirty-five percent (Pena, 1998). It has been shown that 
siblings of patients suffering from CD experience a seven-
teen to thirty-five times greater likelihood of developing 
CD (Akobeng, 2008).
Another significant study performed on ethnic popula-
tions proved that genetic variants are indeed associated 
with CD. People of Ashkenazi Jewish heritage have an in-
creased risk and a higher prevalence in developing CD 
as compared to non-Jews (Baumgart & Sandborn, 2012; 
Newman & Siminovitch, 2003). Several studies have prov-
en that CD is two-to-four times more prevalent among 
individuals of Jewish decent compared to non-Jewish 
Europeans living in the same area (NewsRX Health & 
Science, 2012). Currently, there are seventy-one genet-
ic variants that have been identified in Ashkenazi Jewish 
ancestry that increase an individual’s risk of developing 
CD. (Baumgart & Sandborn, 2012). In a study performed 
examining over six thousand individuals whose Jewish an-
cestry was confirmed by a large number of genetic mark-
ers, several variants were detected that are associated 
with the increased risk of CD. The involvement of twelve 
recognized CD risk variants in Ashkenazi Jews was con-
firmed and identified in novel genetic regions, as opposed 
to in non-Jewish European populations (Kenny et al. 2012). 
Further studies of these regions may aid in the discovery 
of biological pathways affecting susceptibility to CD and 
lead to the development of innovative and more effective 
treatments. This study not only proves the genetic origin 
of CD, but also demonstrates the value of genetic studies 
in secluded ethnicities, such as the Ashkenazim. Jewish 
heritage is an independent risk factor for developing CD. 
Genetic anticipation is the earlier onset of a disease in 
the offspring of parents with the disorder; a phenomenon 
featured in other genetic diseases, it has now been iden-
tified in Crohn’s (Polito et al. 1996).
While genetic studies have been highly successful at 
identifying the genetic risk factors for CD, these studies 
have proven virtually nothing about why one person will 
exhibit only mild symptoms of CD while another patient 
may require surgery to treat their condition. However, a 
familial link is often noticed in the symptoms of related 
patients. Researchers recognize that family members with 
CD often tend to have similar progress through treat-
ments (NewRX, 2017). Furthermore, researchers looked 
at the genome of two thousand seven hundred patients 
who shared similar symptoms and severity of CD. By com-
paring these patient’s DNA, the researchers discovered 
four genetic variants including FOX10, IGFBP1, MHC, and 
XACT that influence the severity of a patient’s condition. 
Strikingly, none of these genes have been shown to affect 
the risk of developing CD. This fact suggests that it is likely 
that genetics not only plays a role in the diagnosis of CD, 
but in the patient’s prognosis as well (Obesity, Fitness & 
Wellness Week, 2017).
Environmental Factors
Although the precise cause for CD is unknown, it’s be-
lieved that environmental factors also play a role in 
the development of the disease. Several environmental 
risk factors, such poor diet, as well as the side effects 
of breastfeeding, smoking, stress, and drugs, are believed 
to trigger inflammation. Additionally, childhood exposure 
towards an overly hygienic environment, seem to allow 
CD to manifest in predisposed patients.
Food is believed to promote the maintenance of gut 
integrity. Although the direct cause and effect relationship 
between the gut microbiota and IBD is unclear, targeting 
the intestinal microbiota allows for prevention of disease, 
as well as potential research concerning new treatments. 
Diet plays a significant role in a patient suffering from 
CD, as the body is unable to digest and absorb food ap-
propriately, thereby causing malnourishment in patients 
with CD (O’Sullivan, 2009). Furthermore, many patients 
with CD are anemic, as well as deficient in vitamin D, folic 
acid and vitamin B12 (Torres et al. 2017; Creek, 2017). 
Patients are recommended to avoid certain foods such as 
raw fruits and vegetables, dairy, fatty, greasy, spicy, and high 
fiber foods, as these foods are more difficult for the body 
to digest and absorb, and commonly irritate the bowel 
(Livie et al. 2006). While it has not been proven that a 
poor diet is a direct cause of CD, research has shown a 
common thread, that a proper diet is helpful in several 
ways by reducing one’s predisposition to developing CD. 
Moreover, diet has also been used as a treatment option 
for CD (Akobeng, 2012). Similar research has proven that 
maintaining a healthy diet is equally as effective in putting 
a patient in remission as corticosteroid treatments, par-
ticularly in the case of children (BMJ, 1997). Nutritional 
repletion is effective both by affecting the gut mucosa 
as well as by decreasing intestinal permeability. There is 
some evidence that the enteral diet has a direct effect on 
the gut mucosa by reducing cytokine production and the 
accompanying inflammation, thus leading to decreased 
intestinal permeability (Hanaway, 2006).
Breastfeeding promotes colonization with microbiota 
such as Bifidobacteria by providing them with the HMOs 
(human milk oligosaccharides) they require to thrive. 
According to one study, when specific HMOs, GOSs 
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(short-chain galactooligosaccharides) and FOSs (long-chain 
fructooligosaccharides), were fed to infants in the first six 
months of life, they later had fewer incidences of autoim-
mune reactions linked to gut microbiota, including recur-
rent wheezing, and allergic urticaria. Accordingly, Crohn’s 
which is an autoimmune disease, may be affected similarly 
by breastfeeding (Torres, et al. 2017). Maternal secretory 
IgA, a component of breast milk has been proven to af-
fect the composition of intestinal microbiota and the ex-
pression of genes associated with intestinal inflammation. 
Additionally, a negative correlation has been found between 
infants’ exposure to breast milk and the development of 
early onset IBD, suggesting breastfeeding has a preventative 
effect on IBD development (Stiemsma et al. 2015).
While cigarette smoking is notorious for initiating 
health risks such as lung cancer and heart disease, it is 
believed to play a role in the development of IBD as well. 
Although the pathogenesis for IBD is unclear, cigarette 
smoking is associated with IBD outcomes as it exacer-
bates the condition. Analysis of multiple studies has con-
firmed that active smokers are at increased risk for ac-
quiring CD (Newman & Siminovitch, 2003). Furthermore, 
smoking has repeatedly been proven to worsen the prog-
nosis of CD as it promotes a fistulizing phenotype, aggra-
vates disease course, and produces a decreased response 
to medical treatment. (Ole et al. 2009). Interestingly, while 
smoking has negative ramifications for Crohn’s sufferers, 
it may have a protective effect on those with a genetic 
disposition towards UC. Active smokers were proven to 
be at a lower risk for developing UC in comparison to 
those who never smoked and those who quit smoking. 
This phenomenon may be linked to nicotinic acetylcho-
line receptors, which are present in mucosal epithelial 
cells of the bowel, as well as on T cells. However, clinical 
trials of nicotine replacement in IBD have only yielded a 
modest benefit at best; thus, nicotine alone may not be 
the driving factor (Ole et al. 2009).
Despite the significant consequences of smoking asso-
ciated with patients suffering from IBD pathogenesis, the 
highest incidence of CD occurs in countries with a low 
prevalence of smoking such as United States and Canada 
(Rook, 2012). Furthermore, the majority of patients with 
CD are not current smokers and the majority of smokers 
do not develop CD, proving that smoking or lack thereof 
likely plays a role in the pathogenesis of only a subset of 
IBD patients (Torres et al. 2017). These studies display little 
correlation between smoking and IBD. Nonetheless, all IBD 
patients should be encouraged to quit smoking due to the 
deleterious negative health effects associated with smoking. 
The role of psychological distress and personality as 
predisposing factors for the development of CD remains 
controversial. The debate concerning this matter has 
been ongoing for over eighty years without reaching a 
common ground, as attempts to investigate the role of 
psychological factors have unveiled conflicting results. 
However, over the past several years, it has become evi-
dent that psychological stress is at least associated with 
CD. However, that stress may be the result rather than 
the cause of chronic and longstanding CD. Unpredictable 
flare-ups and changes in body image can also lead to addi-
tional stress. This stress may precipitate an exacerbation 
of the disorder, thus continuing a vicious cycle of flare ups. 
Multiple theories have been presented suggesting ex-
planations on the unknown environmental exposures 
that may interact with the immune system and result in 
abnormal inflammatory intestinal response. However, the 
most predominant theory is the hygiene hypothesis, which 
explains the link between exposure to specific microbi-
al allergies and the prevention of certain diseases. This 
hypothesis theorizes that when one’s childhood has had 
excess hygiene and a lack of exposure to enteric patho-
gens; the child may not develop sufficient immunity to-
wards pollution and environmental contamination. Thus, 
it will inevitably impair microbial competence of the GI 
immune system and its ability to recognize new antigens, 
thereby predisposing children to immunologic disorders 
further on in life (Sabe et al. 2017). While the effect of 
lack of exposure is believed to be most profound during 
early childhood, the ideal timing and degree of exposure 
required remains unclear. The hygiene hypothesis also 
theorizes that multiple childhood infections and poor hy-
giene protects and prevents an individual from developing 
Crohn’s disease by allowing the host to develop tolerance 
or immunity to agents that may trigger Crohn’s disease 
later on in life (Stiemsma et sl. 2015). Additionally, it is 
entirely probable that the impact of various exposures 
are not mutually exclusive; such that disease development 
depends on the dose-response interactions between ex-
posures, and this reflects how strongly one’s exposure 
may protect or increase the risk conferred by CD sus-
ceptibility mutations) (Sabe et al. 2017).
Interestingly, the first Crohn’s disease gene identified, 
CARD 15(caspase-activation recruitment) also referred 
to as the NOD2 (nucleotide oligomerization domain 
gene), found within IBD1 locus is involved with the in-
nate immune system and the response of monocytes 
upon perceiving a bacterial encounter. The abnormal 
and unconstrained inflammatory response that may 
occur in individuals with NOD2/CARD15 mutations is 
likely to be involved with the pathogenesis of Crohn’s 
disease. Polymorphisms in the CARD15/NOD2/IBD1 
locus have been associated with the highest risk for CD 
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development. Recent evidence shows that polymorphisms 
cause reduced functionality of the immune system and 
exacerbated phenotype (Newman & Siminovitch, 2003). 
Counterintuitively, countries with poor sanitary condi-
tions such as Africa and the Middle East reportedly have 
a relatively low frequency of Crohn’s disease (Torres et 
al. 2017), while more developed countries such as Canada 
and the United States have the highest rates of CD. It is 
believed that endemic parasitic infections may favorably 
affect the immune system as to prevent disease by stim-
ulating T-helper type2 (Th-2) cells, which in turn down-
regulate Th-1 cells and prevent the exaggerated Th-1 re-
sponse associated with Crohn’s disease. Building on this 
theory, the ova of Trichuris suis (eggs of a pig whipworm), 
have been successfully used to treat Crohn’s disease 
patients, as the intake of these parasites elicit Th-2 cells 
thereby suppressing Th-1 cells from activating (Guarneret 
et al. 2006; Summers, et al. 2005).
Many physicians treating patients with IBD do not be-
lieve that stress or diet are direct causes of IBD. Yet, due 
to the lack of understanding of the etiology of IBD, no 
known direct cause and cure exist for the disease. The 
Crohn’s and Colitis Foundation and medical researchers 
suggest that foreign substances found in the environment 
or external agents such as bacteria may interact with a 
weak immune system, thereby producing an immune re-
sponse of inflammation which the body is unable to stop 
(McGovern, Gardet, Törkvist, et al. 2007).
Epigenetics
It has become apparent that epigenetics plays a significant 
role contributing to the development of CD. Epigenetics 
can be defined as mitotically heritable changes in gene 
expression without shifting the DNA. Gene expression 
can be altered by changes to the structure and function of 
chromatin. Different cells in the body are characterized by 
different functions and different levels of gene expression 
despite each sharing the same genetic code. This variation 
in gene activity from cell to cell is achieved by mecha-
nisms and processes that are collectively termed epi-
genetics. The main epigenetic mechanisms include DNA 
methylation, histone modification, RNA interference, and 
the positioning of nucleosomes. These epigenetic mecha-
nisms, in particular DNA, allow the onset and reactivation 
of disease that’s triggered by environmental factors that 
rapidly break the mucosal barrier, thus stimulating an im-
mune response or altering the balance between beneficial 
and pathogenic enteric bacteria. Different genetic abnor-
malities can lead to similar disease phenotypes; these 
genetic changes can be broadly characterized as causing 
defects in mucosal barrier function, immunoregulation 
or bacterial clearance. These new insights will help de-
velop better diagnostic approaches that identify clinically 
important subsets of patients for whom the natural his-
tory of disease and response to treatment are predict-
able. Methylation appears to be of great importance in 
the interaction between genome and the environment. 
Variation in DNA methylation is a well-recognized cause 
of human disease and is likely to play a pivotal role in the 
cause of complex disorders such as CD.
Discussion and Conclusion
Inflammatory bowel disease is sectioned into two divisions, 
CD and UC. Both are complex multifactorial disorders 
characterized by chronic relapsing intestinal inflammation. 
However, the etiology of both diseases remains largely 
unknown as it is characterized as an idiopathic disease 
(Sartor, 2006). Understanding the causes and molecular 
mechanisms of CD and UC is a leading challenge in gas-
troenterology research, due in part to the relatively low 
frequency of these disorders. Although significant effort 
has been made to help identify genetic and environmental 
factors that may increase the risk of IBD, little is known 
about IBD-specific factors.  Recent research has suggested 
that IBD is caused by a complex interplay between genetic 
predispositions of various genes, combined with an abnor-
mal interaction with environmental factors as a result of 
a perceived threat. Epidemiological evidence for a genetic 
contribution is made apparent by twin and family studies 
of CD patients. Genetic variants that stimulate IBD have 
a substantial effect on gene function. These variants are 
so rare in allele frequency, that the genetic signals aren’t 
detected in genome-wide association studies of patients 
with IBD. With recent advances in sequencing techniques, 
roughly fifty genetic disorders have been identified and 
associated with IBD such as osteoporosis as well as thy-
roid disease. Monogenic defects have been found to alter 
intestinal immune homeostasis through many mechanisms. 
Candidate gene resequencing should be carried out in ear-
ly-onset patients in clinical practice.  
The evidence that genetic factors are the prime contrib-
utors to disease pathogenesis confirms the insignificant 
role of microbial and environmental factors. Epigenetic 
factors can mediate interactions between environment 
and genome. Epigenetic mechanisms could affect develop-
ment and progression of IBD. Epigenomics is an emerging 
field, and future studies could provide further insight into 
the pathogenesis of IBD. 
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